Amylyx Pharmaceuticals Q3 Earnings Call Highlights
Nov 5, 12:15 PM·
Medium Optimistic
Tickers
Summary
Amylyx Pharmaceuticals (NASDAQ: AMLX) discussed on its Q3 2026 earnings call, held November 5, 2026, its plans to file for U.S. approval of its experimental post-bariatric hypoglycemia treatment by the end of 2026, following positive late-stage trial results. The company is preparing for a potential launch in 2027.
Amylyx Pharmaceuticals (NASDAQ: AMLX) discussed plans to file for U.S. approval of its experimental post-bariatric hypoglycemia treatment by the end of 2026, following positive late-stage trial results, on its third-quarter 2026 earnings call held November 5, 2026.
The company is preparing for a potential launch in 2027, according to the call.
Call details
- Event: Amylyx Pharmaceuticals Q3 2026 Earnings Call
- Date and time: November 5, 2026, 8:00 AM EST
- Ticker: AMLX
Company participants
- Justin Klee — Co-CEO & Director
- Camille Bedrosian — Chief Medical Officer
- Dan Monahan — Chief Commercial Officer
- James Frates — Chief Financial Officer
- Joshua Cohen — Co-Founder, Co-CEO & Director
- Courtney O’Leary
Conference call participants
- Jacob Ormes — TD Securities Equity Research
- Seamus Fernandez — Guggenheim Securities, LLC, Research Division
- Geoffrey Meacham — Citigroup Inc. Exchange Research
- Marc Goodman — Leerink Partners LLC, Research Division
- Michael DiFiore — Evercore ISI Institutional Equities, Research Division
- Rami Katkhuda — LifeSci Capital, LLC, Research Division
- James Condulis — Stifel, Nicolaus & Company, Incorporated, Research Division
- Samuel Lee — Mizuho Securities USA LLC, Research Division
- Dina Ramadane — BofA Securities, Research Division
- Ananda Ghosh — H.C. Wainwright & Co, LLC, Research Division
- Christopher Chen — Robert W.
The transcript was published on November 6, 2026.